• CF33 patent granted in India, further strengthening global intellectual property protection
• Patent provides method of composition and method of use protection until 2037
• Reinforces Imugene's commitment to advancing its oncolytic virotherapy pipeline

Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, has announced the grant of a patent in India for its exclusively licensed CF33 oncolytic virotherapy technology. The patent, under number 558994, provides method of composition and method of use protection until 2037, adding to the existing patent protection in the United States and Japan within the same oncolytic patent family. This newly granted patent reinforces Imugene's commitment to protecting its CF33 oncolytic virotherapy, a chimeric vaccinia poxvirus developed by Professor Yuman Fong, Chair of Surgical Oncology at City of Hope and a leading expert in oncolytic virus research. Oncolytic viruses are designed to selectively target and destroy cancer cells while simultaneously stimulating the immune system, offering the potential to improve clinical outcomes for patients. Imugene Managing Director and CEO Leslie Chong stated that the grant of this India patent is another significant step in expanding global protection for CF33, building on the company's strong foundation in key markets such as the US and Japan. Imugene remains committed to advancing its oncolytic virotherapy pipeline and delivering next-generation immunotherapies to patients worldwide.